Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday, July 25, transferred an appeal over an award issued in an ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Alkermes (ALKS-3.05%) proved to be a disappointment for investors last year, with its stock slipping while the overall market soared. However, the biotech is off to a pretty good start in 2021.

Alkermes says that after its 2020 “board-led transformation,” in which it “refreshed” 70% of its board, the company has improved its operations significantly. Related.

This collaboration aligns the interests of Alkermes and Biogen in the successful development and commercialization of ALKS 8700 as an important potential treatment option for patients suffering ...